| |
Acceptability and tolerability of long-acting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV (IMPAACT 2017/MOCHA): a secondary analysis of a phase 1/2, multicentre, open-label, non-comparative dose-finding study
|
| |
| |
Download the PDF
April 2024
Elizabeth D Lowenthal, Jennifer Chapman, Rachel Ohrenschall, Katherine Calabrese, Kristin Baltrusaitis, Barbara Heckman, Dwight E Yin, Allison L Agwu, Conn Harrington, Rodica M Van Solingen-Ristea, Cynthia C McCoig, Adeola Adeyeye, Jared Kneebone, Vasiliki Chounta, Christiana Smith-Anderson, Andres Camacho-Gonzalez, Jessica D’Angelo, Allison Bearden, Herta Crauwels, Jenny Huang, Sarah Buisson, Ryan Milligan, Shawn Ward, Carolyn Bolton-Moore*, Aditya H Gaur*, IMPAACT 2017 Collaborators†, for the IMPAACT 2017 Team
Summary
Background
Long-acting injectable cabotegravir and rilpivirine have demonstrated safety, acceptability, and efficacy in adults living with HIV-1. The IMPAACT 2017 study (MOCHA study) was the first to use these injectable formulations in adolescents (aged 12–17 years) living with HIV-1. Herein, we report acceptability and tolerability outcomes in cohort 1 of the study.
Methods
In this a secondary analysis of a phase 1/2, multicentre, open-label, non-comparative dose-finding study, with continuation of pre-study oral combination antiretroviral treatment (ART), 55 adolescents living with HIV-1 were enrolled to receive sequential doses of either long-acting cabotegravir or rilpivirine and 52 received at least two injections. Participants had a body weight greater than 35 kg and BMI less than 31·5 kg/m2 and had been on stable ART for at least 90 consecutive days with an HIV-1 viral load of less than 50 copies per mL at a participating IMPAACT study site. Participants had to be willing to continue their pre-study ART during cohort 1. The primary objectives of the study were to confirm doses for oral and injectable cabotegravir and for injectable rilpivirine in adolescents living with HIV. This analysis of participant-reported outcomes included a face scale assessment of pain at each injection and a Pediatric Quality of Life Inventory (PedsQL) at baseline and week 16 for participants in the USA, South Africa, Botswana, and Thailand. A subset of 11 adolescents and 11 parents or caregivers in the USA underwent in-depth interviews after receipt of one or two injections.
Findings
Between March 19, 2019, and Nov 25, 2021, 55 participants were enrolled into cohort 1. Using the six-point face scale, 43 (83%) of participants at week 4 and 38 (73%) at week 8 reported that the injection caused “no hurt” or “hurts little bit”, while only a single (2%) participant for each week rated the pain as one of the two highest pain levels. Quality of life was not diminished by the addition of one injectable antiretroviral. In-depth interviews revealed that parents and caregivers in the USA frequently had more hesitancy than adolescents about use of long-acting formulations, but parental acceptance was higher after their children received injections.
Interpretation
High acceptability and tolerability of long-acting cabotegravir or rilpivirine injections suggests that these are likely to be favoured treatment options for some adolescents living with HIV.
Funding
National Institutes of Health and ViiV Healthcare.
|
|
| |
| |
|
|
|
